Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares OutstandingShares Outstanding
Ratios

Iradimed (IRMD) EBIAT (2016 - 2026)

Iradimed has reported EBIAT over the past 14 years, most recently at $5.8 million for Q1 2026.

  • Quarterly EBIAT rose 24.13% to $5.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $23.6 million through Mar 2026, up 19.34% year-over-year, with the annual reading at $22.5 million for FY2025, 16.88% up from the prior year.
  • EBIAT was $5.8 million for Q1 2026 at Iradimed, down from $6.4 million in the prior quarter.
  • Over five years, EBIAT peaked at $6.4 million in Q4 2025 and troughed at $2.5 million in Q1 2022.
  • The 5-year median for EBIAT is $4.7 million (2025), against an average of $4.6 million.
  • The largest YoY upside for EBIAT was 120.53% in 2022 against a maximum downside of 5.63% in 2022.
  • A 5-year view of EBIAT shows it stood at $3.7 million in 2022, then increased by 23.58% to $4.5 million in 2023, then grew by 13.37% to $5.1 million in 2024, then increased by 25.17% to $6.4 million in 2025, then fell by 9.69% to $5.8 million in 2026.
  • Per Business Quant, the three most recent readings for IRMD's EBIAT are $5.8 million (Q1 2026), $6.4 million (Q4 2025), and $5.6 million (Q3 2025).